Validation of the positive compounds on solid media assays. (a–c) The motor defect phenotype observed in ATXN3-CAG89 worms was significantly rescued when treated with (a) butaclamol (**P < 0.01), or naphazoline, diacerein, chlorpropamide, sulfaphenazole, etodolac, octoclothepin (****P < 0.0001 for all previous compounds); (b) isotretinoin (***P < 0.001), ibuprofen, alfacalcidol, cylclophosphamide, nomifensine, methiothepin, biotin (****P < 0.0001 for all mentioned compounds); (c) benserazide, digitonin, acetamide, cyclobenzaprine, chenodiol, fenbufen, and cycloheptadine (****P < 0.0001 for all previous compounds) (by log-rank (Mantel-Cox) test, N = 90–100 per trial, and N = 270–300 when all trials combined). No rescue of the locomotion defect is observed when the ATXN3-CAG89 worms were treated with phorbol 12-myristate 12-acetate, lamotrigine, or clebopride. The concentration of the compounds was tested at 20 μM as in the liquid culture. This experiment was done 3 times